Nkarta Therapeutics is a biopharmaceutical company developing allogeneic, off-the-shelf engineered natural killer (NK) cell therapies using proprietary CAR NK technology. The company's lead program is NKX019, a CAR NK cell product candidate targeting CD19 for treating B-cell-mediated autoimmune diseases; unlike autologous therapies that require individualized manufacturing for each patient, NKX019 is produced in quantity from healthy donor cells, cryopreserved, and ready for use, with manufacturing costs spread across hundreds of doses per run. Nkarta intends to generate revenue through commercialization of NKX019 and future CAR NK candidates upon regulatory approval, competing against various cell therapy, antibody, and targeted protein approaches for patients with high unmet medical needs in autoimmune disease.